Info

🌱 來自: upfront treatment of acute myelogenous leukemia (AML)

IDH1_IDH2 mutation

• 20% of AML
• isocitrate dehydrogenase (IDH) genes,
• IDH1 or IDH2.

adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

• ivosidenib
• enasedinib